Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
1998 2
2002 1
2003 2
2005 7
2006 9
2007 7
2008 8
2009 7
2010 2
2011 3
2012 5
2013 4
2014 3
2015 4
2017 4
2018 5
2019 2
2020 1
2021 4
2022 1
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Vergote I, et al. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806. N Engl J Med. 2010. PMID: 20818904 Free article. Clinical Trial.
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
Loverix L, Vergote I, Busschaert P, Vanderstichele A, Venken T, Boeckx B, Harter P, Brems H, Van Nieuwenhuysen E, Pignata S, Baert T, Gonzalez-Martin A, Han S, Marth C, Neven P, Colombo N, Berteloot P, Mäenpää J, Olbrecht S, Laga T, Sablon E, Ray-Coquard I, Pujade-Lauraine E, Lambrechts D, Van Gorp T. Loverix L, et al. Among authors: berteloot p. Eur J Cancer. 2023 Jul;188:131-139. doi: 10.1016/j.ejca.2023.04.020. Epub 2023 Apr 27. Eur J Cancer. 2023. PMID: 37245441
Neoadjuvant chemotherapy for ovarian cancer.
Vergote I, van Gorp T, Amant F, Neven P, Berteloot P. Vergote I, et al. Among authors: berteloot p. Oncology (Williston Park). 2005 Nov;19(12):1615-22; discussion 1623-30. Oncology (Williston Park). 2005. PMID: 16396153 Free article. Review.
Timing of debulking surgery in advanced ovarian cancer.
Vergote I, van Gorp T, Amant F, Leunen K, Neven P, Berteloot P. Vergote I, et al. Among authors: berteloot p. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:11-9. doi: 10.1111/j.1525-1438.2007.01098.x. Int J Gynecol Cancer. 2008. PMID: 18336393 Review.
Adverse events with everolimus in BOLERO-2.
Neven P, Poppe A, Berteloot P, Wolter P, Wildiers H. Neven P, et al. Among authors: berteloot p. Ann Oncol. 2014 Sep;25(9):1861. doi: 10.1093/annonc/mdu195. Epub 2014 May 29. Ann Oncol. 2014. PMID: 24875799 Free article. No abstract available.
Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Floris G, Richard F, Hamy AS, Jongen L, Wildiers H, Ardui J, Punie K, Smeets A, Berteloot P, Vergote I, De Croze D, Meseure D, Salomon A, Laé M, Reyal F, Biganzoli E, Neven P, Desmedt C. Floris G, et al. Among authors: berteloot p. J Natl Cancer Inst. 2021 Feb 1;113(2):146-153. doi: 10.1093/jnci/djaa090. J Natl Cancer Inst. 2021. PMID: 33152071 Free PMC article.
72 results